<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38813382</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Corrigendum: Case Series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequalae of COVID (PASC).</ArticleTitle><Pagination><StartPage>1375607</StartPage><MedlinePgn>1375607</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1375607</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2024.1375607</ELocationID><Abstract><AbstractText>[This corrects the article DOI: 10.3389/fmed.2023.1122529.].</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Patterson, Yogendra, Guevara-Coto, Mora-Rodriguez, Osgood, Bream, Parikh, Kreimer, Jeffers, Rutland, Kaplan and Zgoda.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Bruce K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>IncellDX Inc., San Carlos, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yogendra</LastName><ForeName>Ram</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Beth Israel Lahey Health, Burlington, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guevara-Coto</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Cirug&#xed;a y C&#xe1;ncer (CICICA), Universidad de Costa Rica, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora-Rodriguez</LastName><ForeName>Rodrigo A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Lab of Tumor Chemosensitivity, CIET/DC Lab, Faculty of Microbiology, Universidad de Costa Rica, San Jose, Costa Rica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osgood</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, St. Francis Medical Center, Trenton, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bream</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Novant Health Kernersville Medical Center, Kernersville, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parikh</LastName><ForeName>Purvi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Allergy and Immunology, NYU Langone Tisch Hospital, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreimer</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, New York Presbyterian Hospital, Brooklyn, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeffers</LastName><ForeName>Devon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Stamford Hospital, Stamford, CT, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutland</LastName><ForeName>Cedric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rutland Medical Group, Newport Beach, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Community and Family Medicine, Georgetown University Medical Center, Washington, DC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zgoda</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Creighton University School of Medicine, Phoenix, AZ, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>Front Med (Lausanne). 2023 Feb 08;10:1122529. doi: 10.3389/fmed.2023.1122529</RefSource><PMID Version="1">36844201</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CCR5 antagonist</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">fractalkine (CX3CR1)</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">maraviroc</Keyword><Keyword MajorTopicYN="N">statins</Keyword></KeywordList><CoiStatement>IncellDX holds the patent for the use of CCR5 antagonists (maraviroc) in COVID and long COVID. BP and the founder and CEO of IncellDX and a physician partner of the Chronic COVID Treatment Center (CCTC). The CCTC is a data analytics consulting physician practice that is financially independent from IncellDX. Except for BP, no one from the CCTC has received nor holds any financial or equity compensation from IncellDX. The CCTC IRB is financially independent of IncellDX and CCTC and no one from the IRB has received any financial or equity compensation from IncellDX or CCTC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>30</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38813382</ArticleId><ArticleId IdType="pmc">PMC11135631</ArticleId><ArticleId IdType="doi">10.3389/fmed.2024.1375607</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>